Acute myeloid leukemia (AML) is an invasive hematopoietic malignancy requiring novel treatment strategies. The PDE3A inhibitor anagrelide (ANA) profoundly suppresses the proliferation of high PDE3A-ex
Acute myeloid leukemia (AML) is a malignant hematopoietic disease with poor prognosis for most patients. Conventional chemotherapy has been the standard treatment approach for AML in the past 40 years
To identify a novel clinically-relevant therapy, fluvastatin and matrix bound nanovesicles (MBV) were focused in this study. We found that fluvastatin and MBV synergistically enhance optic nerve regen
